











Bronchiectasis



DR. SHAFIEPOUR/PULMONOLOGIST


Bronchiectasis refers to an irreversible airway dilation that involves the lung in either a focal or a diffuse manner and that classically has been categorized as cylindrical or tubular (the most common form), varicose, or cystic





Etiology: Bronchiectasis can arise from infectious or noninfectious causes

Clues to the underlying etiology often are provided by the pattern of lung involvement.



Major Etiologies of Bronchiectasis and Proposed Workup


ETIOLOGY BY CATEGORY (EXAMPLES)	WORKUP
Obstruction (aspirated foreign body, tumor mass)	Chest imaging (chest x-ray and/or chest CT); bronchoscopy
Infection (bacterial, nontuberculous mycobacterial)	Sputum Gram's stain/ culture; stains/cultures for acid-fast bacilli and fungi. If no pathogen is identified, consider bronchoscopy with bronchoalveolar lavage.
Immunodeficiency (hypogammaglobulinemia, HIV infection, bronchiolitis obliterans after lung transplantation)	Complete blood count with differential; immunoglobulin measurement; HIV testing
Genetic causes (cystic fibrosis, Kartagener's syndrome, α_1 antitrypsin deficiency)	Measurement of chloride levels in sweat (for cystic fibrosis), α_1 antitrypsin levels; nasal or respiratory tract brush/biopsy (for dyskinetic/immotile cilia syndrome); genetic testing
Autoimmune or rheumatologic causes (rheumatoid arthritis, Sjögren's syndrome, inflammatory bowel disease); immune-mediated disease (allergic bronchopulmonary aspergillosis)	Clinical examination with careful joint exam, serologic testing (e.g., for rheumatoid factor). Consider workup for allergic bronchopulmonary aspergillosis, especially in patients with refractory asthma.⁹
Recurrent aspiration	Test of swallowing function and general neuromuscular strength
Miscellaneous (yellow nail syndrome, traction bronchiectasis from postradiation fibrosis or idiopathic pulmonary fibrosis)	Guided by clinical condition


EPIDEMIOLOGY:

the epidemiology of bronchiectasis varies greatly with the underlying etiology. For example, patients born with CF often develop significant clinical bronchiectasis in late adolescence or early adulthood, although atypical presentations of CF in adults in their thirties and forties are also possible. In contrast, bronchiectasis resulting from MAC infection classically affects nonsmoking women >50 years of age. In general, the incidence of bronchiectasis increases with age. Bronchiectasis is more common among women than among men. Bronchiectasis may also frequently be co-diagnosed with chronic obstructive pulmonary disease (COPD) or asthma.

PATHOGENESIS AND PATHOLOGY:


Bronchiectasis Cycle





CLINICAL MANIFESTATIONS :

The most common clinical presentation is a persistent productive cough with ongoing production of thick, tenacious sputum



Clinical presentation

w **The production of large quantities of purulent and often foul-smelling sputum.**

The volume of sputum can be used for estimating the severity of the disease

- ♦ Mild < 10 mL
- ♦ Moderate 10~150 mL
- ♦ Severe >150 mL


⊗ **Dry bronchiectasis**

usually involve the upper lobes


DIAGNOSIS:

The diagnosis usually is based on presentation with a persistent chronic cough and sputum production accompanied by consistent radiographic features

Chest X-ray (frontal view)



B) Chest CT scan (axial view)







Bronchiectasis

The chest radiograph is generally the first radiologic test requested by the pulmonologist when a diagnosis of bronchiectasis is suspected. Unfortunately, because there are key issues of sensitivity and specificity, the chest radiograph has limited value in the diagnosis of bronchiectasis








Figure 1: CT scan with tree-in-bud pattern






Figure 2: Drawing rendition of tree-in-bud

APPROACH TO THE PATIENT Bronchiectasis





Evaluation

- After the diagnosis of bronchiectasis, we need to identify
 - **potentially treatable causes,**
 - **microbiologic pathogens, and**
 - **functional assessment**

Evaluation

- Personal history: childhood symptoms, infertility, previous pneumonia/viral illness, gastric aspiration, asthma, joints pain or deformity
- Family history: primary ciliary dyskinesia (PCD) (**Kartagener's syndrome** – sinusitis, situs inversus and bronchiectasis), cystic fibrosis (CF)


Evaluation

- Investigations:
 - Full blood count with differential
 - Immunoglobulin levels (IgG, IgM and IgA), consider IgE when eosinophilia
 - Rheumatoid factor
 - Sputum smear and culture for bacteria, mycobacteria (NTM) and fungi (mainly *Aspergillus*)

Additional Tests

- Testing for cystic fibrosis
 - Sweat chloride (minimum 2 requirements) and/or mutation analysis of the cystic fibrosis transmembrane conductance regulator (CFTR) gene (if clinical suspicion high)
- Nasal nitric oxide test
- Alpha-1 antitrypsin level and genotype
- HIV antibody test
- Swallow study/pH monitoring
- Bronchoscopy

Aetiological Workup of Bronchiectasis



TREATMENT

ANTIBIOTIC TREATMENT

Antibiotics targeting the causative or presumptive pathogen (with *Haemophilus influenzae* and *P. aeruginosa* isolated commonly) should be administered in acute exacerbations, usually for a minimum of 7–10 days and perhaps for as long as 14 days

diagnostic criteria for true clinical infection with NTM

should be considered in patients with symptoms and radiographic findings of lung disease who have at

least two sputum samples positive on culture;
at least one bronchoalveolar lavage (BAL) fluid sample positive on culture;

a biopsy sample displaying histopathologic features of NTM infection (e.g., granuloma or a positive stain for acid-fast bacilli) along with one positive sputum culture; or a pleural fluid sample (or a sample from another sterile extrapulmonary site) positive on culture.

BRONCHIAL HYGIENE

The numerous approaches used to enhance secretion clearance in bronchiectasis include **hydration** and **mucolytic** administration, aerosolization of bronchodilators and **hyperosmolar agents** (e.g., hypertonic saline), and chest **physiotherapy** (e.g., postural drainage, traditional mechanical chest percussion via hand clapping to the chest, or use of devices such as an **oscillatory positive** expiratory pressure flutter valve or a high-frequency chest wall oscillation vest).

ANTI-INFLAMMATORY THERAPY

It has been proposed that control of the inflammatory response may be of benefit in bronchiectasis, and relatively small-scale trials have yielded evidence of alleviated **dyspnea**, **decreased need for inhaled β -agonists**, and **reduced sputum production** with inhaled glucocorticoids. However, **no significant** differences in **lung function** or bronchiectasis **exacerbation rates** have been observed

duadministration of oral/systemic glucocorticoids due to certain etiologies, such as **ABPA**, or of noninfectious bronchiectasis due to underlying conditions, especially that in which an **autoimmune** condition is believed to be active (e.g., rheumatoid arthritis or Sjögren's syndrome). Patients with ABPA also may benefit from a prolonged course of treatment with the oral antifungal agent **itraconazole**.

REFRACTORY CASES

In select cases, **surgery** can be considered, with resection of a focal area of suppuration. In advanced cases, lung **transplantation** can be considered.

COMPLICATIONS

In more severe cases of infectious bronchiectasis, recurrent infections and repeated courses of antibiotics can lead to microbial **resistance to antibiotics**.

Recurrent infections can result in injury to superficial mucosal vessels, with bleeding and, in severe cases, life-threatening **hemoptysis**

PROGNOSIS

Outcomes of bronchiectasis can vary widely with the **underlying etiology and comorbid conditions** and also may be influenced by the frequency of **exacerbations** and (in infectious cases) the specific pathogens involved (with worse outcomes associated with *P. aeruginosa* colonization).

the decline of lung function in patients with non-CF bronchiectasis was similar to that in patients with COPD, with the forced expiratory volume in 1 s (**FEV1**) declining by **50–55 mL per year as opposed to 20–30 mL** per year for healthy controls

PREVENTION

Reversal of an underlying immunodeficient state (e.g., by administration of **gamma globulin for immunoglobulin-deficient** patients) and **vaccination** of patients with chronic respiratory conditions (e.g., **influenza and pneumococcal vaccines**) can decrease the risk of recurrent infections. Patients who smoke should be counseled about smoking cessation.

After resolution of an acute infection in patients with recurrences (e.g., **≥ 3 episodes per year**), the use of suppressive antibiotics to minimize the microbial load and reduce the frequency of exacerbations has been proposed.


BRONCHIECTASIS

- IRREVERSIBLE DILATION OF THE AIRWAY DUE TO INFLAMMATORY DESTRUCTION OF AIRWAY WALLS RESULTING FROM PERSISTENTLY INFECTED MUCUS
- *P. AERUGINOSA* IS THE MOST COMMON PATHOGEN
- CLINICAL MANIFESTATION INCLUDE CHRONIC COUGH COPIOUS MUCOPURULENT EXPECTORATION
- COMMON IN PATIENTS WITH CYSTIC FIBROSIS

SIGNS AND SYMPTOMS




AETIOLOGY




MANAGEMENT



TREAT UNDERLYING CONDITION (IE. CYSTIC FIBROSIS, COPD)



PATHOLOGY



EXACERBATIONS - SEVERE






MICROBIAL SPUTUM OF PATIENTS FREQUENTLY FOUND TO BE COLONIZED WITH PATHOGENIC MICROORGANISMS

SPUTUM CULTURE AND SENSITIVITY

INVESTIGATIONS



COMPLICATION



Armando H. Falgout



از حسن توجه شما سپاسگزارم